A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.

ABSTRACT:

Background

Chikungunya virus (CHIKV) is a re-emerging arbovirus associated with febrile illness often accompanied by rash and arthralgia that may persist for several years. Outbreaks are associated with high morbidity and create a public health challenge for countries affected. Recent outbreaks have occurred in both Europe and the Americas, suggesting CHIKV may continue to spread. Despite the sustained threat of the virus, there is no approved vaccine or antiviral therapy against CHIKV. Therefore, it is critical to develop a vaccine that is both well tolerated and highly protective.

Methodology/principal findings

In this study, we describe the construction and characterization of a modified Vaccinia virus Ankara (MVA) virus expressing CHIKV E3 and E2 proteins (MVA-CHIK) that

SUBMITTER: Weger-Lucarelli J 

PROVIDER: S-EPMC4109897 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature